Genmin Ltd
ASX:GEN
Genmin Ltd
ASX:GEN
Price:
0.007
AUD
Market Closed
Market Cap:
AU$24.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Genmin Ltd
ASX:GEN
|
AU |
|
Northwest Natural Holding Co
NYSE:NWN
|
US |
|
OptiBiotix Health PLC
LSE:OPTI
|
UK |
|
O
|
OpenSys (M) Bhd
KLSE:OPENSYS
|
MY |
|
A
|
Atlan Holdings Bhd
KLSE:ATLAN
|
MY |
|
Agilysys Inc
NASDAQ:AGYS
|
US |
|
HG Infra Engineering Ltd
BSE:541019
|
IN |
|
Mav Beauty Brands Inc
TSX:MAV
|
CA |
|
C
|
Chromocell Therapeutics Corp
AMEX:CHRO
|
US |
|
H
|
HansaeMK Co Ltd
KRX:069640
|
KR |
|
Bank Victoria International Tbk PT
IDX:BVIC
|
ID |
|
A
|
Anglo American Platinum Ltd
JSE:AMS
|
ZA |
|
V
|
Vinafreight JSC
VN:VNF
|
VN |
|
Solytech Enterprise Corp
TWSE:1471
|
TW |
|
K
|
Klaipedos Nafta AB
F:XIC
|
LT |
|
Golden Agri-Resources Ltd
SGX:E5H
|
SG |
|
YOUZU Interactive Co Ltd
SZSE:002174
|
CN |
|
Ozon Holdings PLC
MOEX:OZON
|
CY |
|
Yesco Holdings Co Ltd
KRX:015360
|
KR |
|
G
|
Grodno SA
WSE:GRN
|
PL |
|
H
|
Hua Eng Wire And Cable Co Ltd
TWSE:1608
|
TW |
|
S
|
Spectrum Pharmaceuticals Inc
F:NTR
|
US |
|
H
|
Hongchang International Co Ltd
OTC:HCIL
|
CN |
|
C
|
Cooper Metals Ltd
ASX:CPM
|
AU |
Income Statement
Earnings Waterfall
Genmin Ltd
Genmin Ltd
Income Statement
Genmin Ltd
Genmin Ltd
Currency: USD
| Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
2
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
+1 550%
|
0
+120%
|
0
-35%
|
0
-68%
|
0
+83%
|
0
-9%
|
0
-40%
|
0
+267%
|
0
+27%
|
0
-54%
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(2)
|
(1)
|
(3)
|
(5)
|
(6)
|
(10)
|
(11)
|
(10)
|
(9)
|
(12)
|
(11)
|
|
| Selling, General & Administrative |
(2)
|
(3)
|
(4)
|
(5)
|
(5)
|
(8)
|
(9)
|
(9)
|
(8)
|
(10)
|
(10)
|
|
| Research & Development |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
|
| Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other Operating Expenses |
0
|
2
|
1
|
1
|
(1)
|
(2)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
|
| Operating Income |
(2)
N/A
|
(1)
+43%
|
(3)
-109%
|
(5)
-67%
|
(6)
-26%
|
(10)
-65%
|
(11)
-15%
|
(10)
+11%
|
(9)
+7%
|
(12)
-26%
|
(11)
+5%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
(1)
|
(1)
|
0
|
0
|
(0)
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(3)
N/A
|
(2)
+23%
|
(4)
-85%
|
(6)
-46%
|
(8)
-37%
|
(12)
-54%
|
(13)
-7%
|
(12)
+9%
|
(11)
+5%
|
(14)
-22%
|
(14)
-2%
|
|
| Net Income | ||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(3)
|
(2)
|
(4)
|
(6)
|
(8)
|
(12)
|
(13)
|
(12)
|
(11)
|
(14)
|
(14)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(3)
N/A
|
(2)
+23%
|
(4)
-85%
|
(6)
-46%
|
(8)
-38%
|
(12)
-54%
|
(13)
-7%
|
(12)
+9%
|
(11)
+5%
|
(14)
-22%
|
(14)
-2%
|
|
| EPS (Diluted) |
-0.01
N/A
|
-0.01
N/A
|
-0.01
N/A
|
-0.01
N/A
|
-0.02
-100%
|
-0.03
-50%
|
-0.03
N/A
|
-0.02
+33%
|
-0.01
+50%
|
-0.01
N/A
|
-0.01
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
